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ABSTRACT 
Head and neck squamous cell carcinoma (HNSCC) includes epithelial cancers of the oral and 
nasal cavity, larynx, and pharynx and accounts for ~350,000 deaths/year worldwide. Smoking-
related HNSCC is associated with few targetable mutations but is defined by frequent copy 
number alteration, the most common of which is gain at 3q. Critical 3q target genes have not 
been conclusively determined for HNSCC. Here we present data indicating that MAP3K13 
(encoding LZK) is an amplified driver gene in HNSCC. Copy number gain at 3q resulted in 
increased MAP3K13 mRNA in HNSCC tumor samples and cell lines. Silencing LZK reduced 
cell viability and proliferation of HNSCC cells with 3q gain but not control cell lines. Inducible 
silencing of LZK caused near complete loss of colony-forming ability in cells harboring 3q gain. 
These results were validated in vivo by evidence that LZK silencing was sufficient to reduce 
tumor growth in a xenograft model of HNSCC. Our results establish LZK as critical for 
maintaining expression of mutant stabilized p53. 
 
INTRODUCTION 
HNSCC is driven by frequent copy number alteration, the most common of which is gain of 3q, 
the long arm of chromosome 3 (1). Drivers identified on the 3q amplicon include PIK3CA (2,3), 
TP63 (4-6), and SOX2 (7-9); however, targeting amplified PIK3CA has displayed limited success 
(10,11), and small molecule inhibitors do not exist for SOX2 or p63, thus additional drivers must 
be identified to improve outcomes for HNSCC patients. We investigated the kinase LZK 
(encoded by MAP3K13, a resident gene on the 3q amplicon) as a novel target because it was 
previously reported to regulate the JNK (12,13) and NFNB (14) pathways, which can be pro-
tumorigenic. There are few studies describing the function of LZK, but a previous study 
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demonstrated that LZK and its close family member DLK play a role in synaptic growth. 
Specifically, the DLK/LZK Drosophila homolog, wallenda, is required for synaptic overgrowth 
(15), and overexpression of LZK can promote axon growth in neurons (16). In addition, 
'/./=. LQKLELWRUV KDYH EHHQ GHYHORSHG DQG VKRZ DFWLYLW\ LQ D 3DUNLQVRQ¶V GLVHDVH PRXVH
model (17).  
Mutation or deletion of TP53 (encoding p53) is a frequent and early event in the 
development of HNSCC (1). Wild-type p53 is a critical tumor suppressor; however, many 
TP53 mutations produce a full-length protein, which is highly expressed in cancer cell lines 
(18). Several hotspot mutations have been identified and demonstrated to have oncogenic 
capabilities (reviewed in 19,20), including the ability to transform p53-null cells and promote 
tumor growth in mice (21). Gain-of-function (GOF) p53 mutants are associated with anti-
apoptotic (22,23), pro-proliferative (24-26) and pro-invasive phenotypes (25,27), and can 
promote resistance to chemotherapy (24,28). GOF p53 mutants have been shown to upregulate 
cyclins A and B1 (26), hTERT (29), MDR1 (21) 1)ț% (30) and MYC (31), and 
downregulate p21, PTEN, BAX (22) and caspase-3 (28). GOF p53 has also been shown to 
interact with and inhibit AMPK (32), and modulate chromatin regulatory factors, including 
MLL1, MLL2, and MOZ (33). GOF mutant p53 is stabilized by tumor cell-specific factors 
(34), the mechanisms of which are not fully understood. Currently, no therapeutics have been 
specifically developed to suppress the expression of stabilized mutant p53; however, HSP90 
inhibitors were previously shown to reduce expression of mutant p53 (23). Here we describe 
LZK as essential to maintain proliferation of HNSCC cells with 3q gain, via promoting 
stability of GOF mutant p53.  
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0$7(5,$/6$1'0(7+2'6 
3ODVPLGVDQGWUDQVIHFWLRQV 
/=. F'1$ ZDV SUHSDUHG IURP 51$ H[WUDFWHG IURP 7 FHOOVDWW% IODQNLQJ UHJLRQV ZHUH
DGGHGE\3&5DQGWKH%3FORQDVHUHDFWLRQXVHGWRLQVHUW/=.LQWRS'215From here the 
Invitrogen Gateway system was used for cloning into destination vectors. FLAG-tagged 
(pReceiver-M12, GeneCopoeia) destination vector was converted into Gateway destination 
vector for use in transient overexpression assays.7KHS/HQWL729-'(67YHFWRUZDVXVHG
WR JHQHUDWH VWDEOH RYHUH[SUHVVLRQ 0XWDWLRQV ZHUH LQWURGXFHG XVLQJ D 6LWH-'LUHFWHG
0XWDJHQHVLV .LW 6WUDWDJHQH .LQDVH GHDG .' FRQVWUXFW XVHG IRU /=. ZDV D .0
PXWDQW )RU WKH VK51$-UHVLVWDQW /=. FRQVWUXFW PXWDWLRQV ZHUH DV IROORZV g978t, t981c, 
a984g, t987a, c990g, t993c, a996g. 
7&$/DQG%($6%FHOOVZHUHWUDQVLHQWO\WUDQVIHFWHGXVLQJ$WWUDFWHQH4LDJHQ
DFFRUGLQJWRPDQXIDFWXUHU¶VSURWRFRO%,&5FHOOVZHUHWUDQVIHFWHGXVLQJ/LSRIHFWDPLQH/7;
	 3OXV UHDJHQW ,QYLWURJHQ DFFRUGLQJ WR PDQXIDFWXUHU¶V SURWRFRO $ SF'1$ YHFWRU
,QYLWURJHQ ZDV XVHG DV DQ HPSW\ YHFWRU FRQWURO ZKHUH UHTXLUHG 'KDUPD)(&7 7KHUPR
6FLHQWLILFZDVXVHGIRUVL51$WUDQVIHFWLRQVVL51$XVHGIRU/=.ZDVREWDLQHGIURP2ULJHQH
DQG XVHG DW  Q0 6HTXHQFHV ZHUH DV IROORZV **$$&$&*$8*$$8&$*$*$&**&*
VL/=.$ **&*$$8$$888$8$&$8**$$87* VL/=.% DQG
$*$$&$*$$8*$*$&**$8$8&$$*VL/=.&VL51$WRSZDVRUGHUHGIURP6DQWD
&UX] VL-S VF- DQG &HOO 6LJQDOLQJ 7HFKQRORJ\ VL-S  DQG XVHG DW
 Q01RQ-WDUJHWLQJFRQWURO VL51$ZDVRUGHUHG IURP'KDUPDFRQ '--- DQG
XVHG DW WKH VDPH FRQFHQWUDWLRQ DV VL51$ WR WKH DSSURSULDWH WDUJHW 6WDXURVSRULQH ZDV
SXUFKDVHGIURP&HOO6LJQDOLQJ7HFKQRORJ\ 
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&HOOFXOWXUH 
&$/ '06= REWDLQHG 2FW  DQG 7 $7&& -XO\  FHOOV ZHUH PDLQWDLQHG LQ
'0(0 ' 6LJPD VXSSOHPHQWHG ZLWK  )%6 /DEWHFK  SHQ-VWUHS *LEFR DQG
 P0*OXWD0$;*LEFR%,&50DUFK%,&5-DQ%,&52FWDQG
%,&51RYDQG$SUDOOREWDLQHGIURP3XEOLF+HDOWK(QJODQGFHOOVZHUHJURZQ
LQ'0(0'ZLWK)%6SHQ-VWUHSJPOK\GURFRUWLVRQH6LJPDDQG P0
*OXWD0$; 06. 06.&& -XO\  DQG %($6% $7&& 2FW  FHOOV ZHUH
PDLQWDLQHG LQ 530,   *OXWD0$; *LEFR ZLWK  )%6 DQG  SHQ-VWUHS
3(-&$3- 3- DQG 3(-&$3- 3- ERWK REWDLQHG -DQ  IURP 3XEOLF +HDOWK
(QJODQG ZHUH FXOWXUHG LQ ,'0(0 ZLWK  )%6  SHQ-VWUHS DQG  P0 *OXWD0$;
'(752,7 $7&& 1RY  FHOOV ZHUH PDLQWDLQHG LQ (0(0 $7&& ZLWK  )%6
DQG SHQ-VWUHS *LEFR )7 ,QYLWURJHQ1RYHPEHU ZHUH PDLQWDLQHG LQ '0(0
ZLWK  )%6  P0 *OXWD0$;  P0 VRGLXP S\UXYDWH *LEFR DQG  P0 1($$
*LEFR2.)7(57FHOOV+DUYDUG6NLQ'LVHDVH5HVHDUFK&HQWHU-XQHZHUHVHHGHG
LQ .-VIP *LEFR ZLWK DFFRPSDQ\LQJ VXSSOHPHQWV  JPO ERYLQH SLWXLWDU\ H[WUDFW
 QJPO(*)P0&D&ODQGSHQ-VWUHS$WFRQIOXHQF\PHGLXPZDVFKDQJHGIRU
 .-VIP'). WR DOORZ JURZWK WR IXOO FRQIOXHQFH '). ZDV FRPSRVHG RI '0(0)
*LEFR ZLWK  P0 *OXWD0$;  JPO ERYLQH SLWXLWDU\ H[WUDFW *LEFR  QJPO (*)
*LEFR P0&D&O/RQ]DDQGSHQ-VWUHS,QFXEDWLRQZDVDWq&DQG&2IRUDOO
FHOOV &HOO OLQHV LQ UHJXODU XVH ZHUH VXEMHFW WR DXWKHQWLFDWLRQ E\ \HDUO\ 675 SURILOLQJ
FRQGXFWHG E\ PXOWLSOH[ 3&5 DVVD\ E\$SSOLHG %LRV\VWHPV$PSIOVWU V\VWHP 675 SURILOHV
ZHUHFRPSDUHGWR$7&&DQG'06=GDWDEDVHV+RZHYHUQRSURILOHZDVDYDLODEOHIRU%,&5
%,&5 06. RU 2.)7(57 FHOO OLQHV DQG %,&5 3- DQG 3- ZHUH RQO\
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UHPRYHGIURPIUHH]HIRUDVKRUWWLPHDIWHUUHFHLSWIRUFROOHFWLRQRI'1$DQG51$VRZHUHQRW
DXWKHQWLFDWHG T VWDWXV RI DOO +16&& DQG LPPRUWDOL]HG FRQWURO FHOO OLQHV ZHUH YHULILHG LQ-
KRXVH$OO FHOO OLQHV ZHUH XVHG LQ H[SHULPHQWV IRU IHZHU WKDQ  SDVVDJHV  ZHHNV DIWHU
WKDZLQJ EHIRUH D IUHVK YLDO ZDV WDNHQ IURP IUHH]H &HOO OLQHV LQ XVH ZHUH FRQILUPHG WR EH
P\FRSODVPD-QHJDWLYHHYHU\±PRQWKV 
 
*HQHUDWLRQRIGR[\F\FOLQH-LQGXFLEOHNQRFNGRZQFHOOOLQHV 
&$/%,&52.)7(57%($6%'(752,7DQG%,&5LQGXFLEOHNQRFNGRZQ
FHOOVZHUHJHQHUDWHGE\6LULRQ%LRWHFK06.DQG%,&5ZHUHJHQHUDWHGLQ-KRXVHXVLQJ
OHQWLYLUDO SDUWLFOHV SURYLGHG E\ 6LULRQ JHQHUDWHG E\ WUDQVIHFWLRQ RI 71 FHOOV ZLWK
H[SUHVVLRQ YHFWRUV DQG OHQWLYLUDO SDFNDJLQJ SODVPLGV 7UDQVGXFWLRQ ZDV DW 02,  ZLWK
 ȝJPOSRO\EUHQH$IWHUKPHGLXPZDVUHSODFHGZLWKIUHVKPHGLXPFRQWDLQLQJSXURP\FLQ
,QYLWURJHQ WR VHOHFW IRU FHOOV WKDWKDGEHHQHIIHFWLYHO\ WUDQVGXFHG VK51$VHTXHQFHVZHUH
&**$$7*$$&&7*7&7&7*$$ VK *$7*7$*$77&77&$*&&$77 VK DQG
$$*$*&&*$7$7&*$$*&$$$ VK 7KH OHQWLYLUDO H[SUHVVLRQ SODVPLG ZDV
S&/9L*-0&6-3XUR ZKLFK H[SUHVVHV D GR[\F\FOLQH-UHVSRQVLYH WUDQVDFWLYDWRU DQG WKH
VK51$IURPWKHVDPHYHFWRU([SUHVVLRQRIWKHWUDQVDFWLYDWRULVFRQVWLWXWLYHZKLOHH[SUHVVLRQ
RI VK51$ LVGHSHQGHQWRQDGR[\F\FOLQH-LQGXFLEOHSURPRWHU%LQGLQJRIGR[\F\FOLQH WR WKH
WUDQVDFWLYDWRUDOORZVLWWRELQGWKHGR[\F\FOLQH-LQGXFLEOHSURPRWHUDQGSURPRWHH[SUHVVLRQRI
WKHVK51$'R[\F\FOLQH6LJPDZDVXVHGDWȝJPOWRLQGXFHNQRFNGRZQRI/=. 
 
*HQHUDWLRQRIWHWUDF\FOLQH-LQGXFLEOHH[SUHVVLRQFHOOOLQHV 
7KH 9LUD3RZHU +L3HUIRUP 7-5H[ *DWHZD\ ([SUHVVLRQ 6\VWHP ,QYLWURJHQ ZDV XVHG WR
JHQHUDWH FHOOV ZLWK WHWUDF\FOLQH-LQGXFLEOH H[SUHVVLRQ RI /=. %ULHIO\ /=. FORQHG LQWR
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S/HQWL729-'(67YHFWRUDQGS/HQWL75IRUWHWUDF\FOLQHUHSUHVVRUH[SUHVVLRQZHUH
WUDQVIHFWHG LQWR )7 FHOOV XVLQJ /LSRIHFWDPLQH WR JHQHUDWH OHQWLYLUDO VWRFN 3DUHQWDO
2.)7(57DQG%($6%FHOOVZHUHWUDQVGXFHGZLWKOHQWLYLUDOVWRFNVLQDVWHSZLVHIDVKLRQ
DQG FHOO OLQHV JHQHUDWHG E\ DQWLELRWLF VHOHFWLRQ %ODVWLFLGLQ ,QYLWURJHQ DQG *HQHWLFLQ
*LEFR7HWUDF\FOLQH,QYLWURJHQZDVXVHGDWȝJPOWRLQGXFHH[SUHVVLRQRI/=. 
 
51$SUHSDUDWLRQ 
 K DIWHU WUHDWPHQW WUDQVLHQW WUDQVIHFWLRQ WHWUDF\FOLQH-LQGXFHG RYHUH[SUHVVLRQ RU
GR[\F\FOLQH-LQGXFHG NQRFNGRZQ FHOOV ZHUH O\VHG XVLQJ 5/7 EXIIHU 4LDJHQ ZLWK  YY
-PHUFDSWRHWKDQRO %LR5DG 5HPRYDO RI JHQRPLF '1$ DQG SUHSDUDWLRQ RI 51$ ZDV
FRQGXFWHGXVLQJDQ51HDV\NLW4LDJHQDFFRUGLQJWRPDQXIDFWXUHU¶VSURWRFRO7KHTXDQWLW\RI
51$ ZDV GHWHUPLQHG XVLQJ D 1DQR'URS 1'- VSHFWURSKRWRPHWHU 1DQR'URS
7HFKQRORJLHV 
 
57-3&5 
57-3&5ZDVSHUIRUPHGXVLQJ6XSHU6FULSW,,,2QH-6WHS57-3&5NLW,QYLWURJHQ3ULPHUVXVHG
ZHUH DV IROORZV $$&7*$77&*$$**&*&$*$ /=. IRUZDUG
***&*7777&&$$*$*$**$ /=. UHYHUVH &&$7**$*$$**&7**** *$3'+
IRUZDUG *7&&$&&$&&&7*77*&7*7$ *$3'+ UHYHUVH 7KH F\FOLQJ FRQGLWLRQV IRU
3&5 ZHUH DV IROORZV F'1$ V\QWKHVLV DQG SUH-GHQDWXUDWLRQ  F\FOH DW  & IRU  PLQ
IROORZHGE\&IRUPLQ3&5DPSOLILFDWLRQF\FOHVRIGHQDWXULQJDW &IRUV
DQQHDOLQJDW&IRUVDQGH[WHQVLRQDW&IRUVDQGDILQDOH[WHQVLRQDW &IRU
 PLQ3&5SURGXFWVZHUHUHVROYHGRQDJDURVHJHODQGYLVXDOL]HGZLWK1DQF\-6LJPD
'1$JHOVWDLQXQGHU89OLJKW 
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T57-3&5 
7KH 3RZHU 6<%5 *UHHQ 51$-WR-&7 -6WHS .LW $SSOLHG %LRV\VWHPV ZDV XVHG IRU
T57-3&5 3ULPHUV XVHG ZHUH DV IROORZV &&777*7&&**$$*7&&&$$$$7*7& /=.
IRUZDUG *$$***7$77***$77*$*&77**7* /=. UHYHUVH 
&&$$&&*&*$*$$*$7*$ $&7% IRUZDUG &&$*$**&*7$&$***$7$* $&7%
UHYHUVH 77&7**&&7**$**&7$7& %0 IRUZDUG
7&$**$$$777*$&777&&$77&%0UHYHUVH6DPSOHVZHUH UXQRQDQ$%,+7
UHDO-WLPH3&5LQVWUXPHQWZLWKWKHIROORZLQJSURJUDPUHYHUVHWUDQVFULSWLRQq& PLQ
DFWLYDWLRQRI'1$SRO\PHUDVHq&PLQ3&5DPSOLILFDWLRQF\FOHVRIGHQDWXULQJDW
&IRUVDQGDQQHDOLQJH[WHQVLRQDW&IRUPLQ6'6VRIWZDUHZDVXVHGWRFRPSXWH
&7YDOXHV*UDSKVGLVSOD\UHODWLYHH[SUHVVLRQRI0$3.FRPSDUHGWRDUHIHUHQFHJHQHDQGD
FRQWUROVDPSOHDVVWDWHGLQWKHUHOHYDQWILJXUHOHJHQG 
 
3URWHLQO\VDWHSUHSDUDWLRQDQGLPPXQREORWV 
$IWHUDSSURSULDWHWUHDWPHQWWLPHFHOOVZHUHO\VHGRQLFHZLWK7ULWRQ;-O\VLVEXIIHU&HOO
6LJQDOLQJ7HFKQRORJ\VXSSOHPHQWHGZLWKSURWHDVH LQKLELWRU WDEOHW5RFKH$QWLERGLHVXVHG
S-1.7< S-S6 *$3'+ S,.%Į6 S$03.Į7 $03.Į S
DQWL-UDEELWDQWL-PRXVH &HOO6LJQDOLQJ7HFKQRORJ\Į-WXEXOLQ)ODJ06LJPDS 6DQWD
&UX] /=. DEFDP S-S7< *HQZD\ 0'0 0LOOLSRUH 0'0 %HWK\O
ODERUDWRULHV 
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3KRVSKRDUUD\V 
7ZRSKRVSKRDUUD\VZHUHXVHGDSKRVSKR-NLQDVHDUUD\DQGD0$3.DUUD\ ERWK IURP5	'
6\VWHPV 6DPSOHV ZHUH O\VHG  K DIWHU LQGXFWLRQ E\ WHWUDF\FOLQH RU GR[\F\FOLQH DV
DSSURSULDWH3URWRFROVZHUHDVPDQXIDFWXUHU¶VLQVWUXFWLRQV 
 
077FHOOYLDELOLW\DVVD\V 
&HOOV ZHUH VHHGHG LQWR -ZHOO SODWHV LQ WULSOLFDWH )RU WUDQVLHQW NQRFNGRZQ FHOOV ZHUH
WUDQVIHFWHG DW WKH VDPH WLPH DV VHHGLQJ DQG DQDO\]HG  K ODWHU )RU LQGXFLEOH NQRFNGRZQ
GR[\F\FOLQHZDVDGGHGLQWRWKHPHGLXPWKHIROORZLQJGD\DQGDQDO\]HGKODWHU077.LW
6LJPDZDVXVHGWRDVVHVVYLDELOLW\XVLQJSURWRFRODVPDQXIDFWXUHU¶VLQVWUXFWLRQV 
 
076FHOOYLDELOLW\DVVD\V 
)RU076DVVD\V&HOO7LWHU$TXHRXV2QH6ROXWLRQFHOOSUROLIHUDWLRQDVVD\3URPHJDZDV
XVHG IROORZLQJ WKH PDQXIDFWXUHU
V SURWRFRO %ULHIO\ FHOOV ZHUH UHYHUVH WUDQVIHFWHG ZLWK WKH
FRUUHVSRQGLQJSVL51$RUQHJDWLYHFRQWURO KODWHUFHOOVZHUHFROOHFWHGDQGVHHGHGLQWR
-ZHOO SODWHV LQ WULSOLFDWH IRU 076 DVVD\ DQG -ZHOO SODWHV IRU SURWHLQ H[WUDFWLRQ
'R[\F\FOLQH ZDV DGGHG ZKHUH DSSURSULDWH DQG FHOOV LQFXEDWHG IRU  K 076 ZDV DGGHG
LQFXEDWHGIRUKDQGDEVRUEDQFHPHDVXUHGDWQP 
 
&HOOSUROLIHUDWLRQDVVD\V 
&HOOVZHUHVHHGHGLQWR-ZHOOSODWHVLQWULSOLFDWHDQGGR[\F\FOLQHDGGHGLQWRWKHPHGLXPWKH
IROORZLQJGD\&HOOVZHUHWUHDWHGIRUKEHIRUHLQFXEDWLRQZLWK%UG8ODEHOIRUDIXUWKHU K
SULRUWRDQDO\VLVE\&DOELRFKHPNLWDFFRUGLQJWRPDQXIDFWXUHU¶VLQVWUXFWLRQV 
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5HODWLYHFHOOGHQVLW\DVVD\V 
&U\VWDOYLROHW DVVD\VZHUHXVHG WRDVVHVV UHODWLYH FHOO JURZWK DQG VXUYLYDO DIWHUNQRFNGRZQ
)RUWUDQVLHQWNQRFNGRZQFHOOVZHUHWUDQVIHFWHGDWWKHVDPHWLPHDVVHHGLQJDQGDQDO\]HGK
ODWHU)RULQGXFLEOHNQRFNGRZQFHOOVZHUHVHHGHGLQWR-ZHOOSODWHVLQWULSOLFDWHWUHDWHGZLWK
GR[\F\FOLQH WKH IROORZLQJ GD\ DQG SODWHV DQDO\]HG DIWHU  K WUHDWPHQW &HOOV ZHUH WKHQ
ZDVKHGZLWK3%6DQGIL[HGLQ LFH-FROGPHWKDQROEHIRUHVWDLQLQJZLWKFU\VWDOYLROHW LQ
 PHWKDQRO )RU TXDQWLILFDWLRQ FU\VWDO YLROHW VWDLQ ZDV GLVVROYHG LQ  DFHWLF DFLG
LQFXEDWHGIRUPLQZLWKVKDNLQJDQGUHDGDWQP 
 
&RORQ\IRUPDWLRQDVVD\V 
&HOOV ZHUH VHHGHG LQWR -ZHOO SODWHV LQ WULSOLFDWH at 300/well (BEAS2B and OKF6/TERT2 
controls) or 1000/well (HNSCC cell lines), DQG WUHDWHG ZLWK GR[\F\FOLQH WKH IROORZLQJ GD\
0HGLXP ZDV UHIUHVKHG HYHU\  K IRU  GD\V &HOOV ZHUH VWDLQHG ZLWK FU\VWDO YLROHW DV
GHVFULEHGDERYH 
 
0DWULJHODVVD\ 
7KHµ'RQ-WRSDVVD\¶ZDVXVHGWRDVVHVVJURZWKLQPDWULJHO0DWULJHOXVHGZDV*URZWK
)DFWRU 5HGXFHG 3KHQRO 5HG-)UHH %DVHPHQW 0HPEUDQH 0DWUL[ IURP PRXVH (+6 WXPRU
&RUQLQJ 0DWULJHO ZDV WKDZHG DW  q& RYHUQLJKW 3ODWHV DQG WLSV ZHUH SUH-FKLOOHG SULRU WR
H[SHULPHQWDQGH[SHULPHQWZDVFRQGXFWHGRQLFHH[FHSWZKHUHVSHFLILHG-ZHOOSODWHVZHUH
FRDWHG ZLWK  ȝO PDWULJHO DQG LQFXEDWHG DW  q& IRU  PLQ &HOOV ZHUH SODWHG DW
ZHOO LQPOPHGLXPDQG OHIW WR VHWWOH IRUPLQ DWq&POPDWULJHO LQ
PHGLXP ZDV DGGHG JHQWO\ WR HDFKZHOO7KH IROORZLQJ GD\ FHOOV ZHUH WUHDWHG ZLWK  ȝJPO
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GR[\F\FOLQHZKHUH UHTXLUHG$IWHUK WUHDWPHQWSODWHVZHUHREVHUYHGZLWKDQ$[LRYHUW
&)/ ,QYHUWHG 0LFURVFRSH DQG SKRWRJUDSKV WDNHQ ZLWK WKH DLG RI$[LR9LVLRQ VRIWZDUH7KH
µ&RORU7KUHVKROG¶ WRRO LQ ,PDJH- ZDV XVHG WR DVVHVV DYHUDJH FRORQ\ VL]H7KUHH LPDJHV SHU
FRQGLWLRQZHUHXVHGIRUPHDVXUHPHQWDQGDYHUDJHFRORQ\VL]HFDOFXODWHGIRUHDFKFRQGLWLRQ 
 
&HOOF\FOHDQDO\VLV 
&HOOV ZHUH VHHGHG LQWR -ZHOO SODWHV DQG WUHDWHG ZLWK GR[\F\FOLQH WKH IROORZLQJ GD\$IWHU
 KPHGLDZLWKIORDWLQJFHOOVZHUHFROOHFWHGWR)$&6WXEHVDQGSODWHVWU\SVLQL]HG7U\VLQL]HG
FHOOV ZHUH DGGHG WR WKH )$&6 WXEHV ZLWK WKH PHGLD WKDW ZHUH SUHYLRXVO\ FROOHFWHG DQG WKH
WXEHV VSXQ IRU  PLQ DW  USP 6XSHUQDWDQW ZDV GLVFDUGHG DQG  PO SUH-FKLOOHG HWKDQRO
DGGHGGURSZLVHWRHDFKWXEHZKLOHYRUWH[LQJ&HOOVZHUHNHSWDW-&XQWLODQDO\VLV$%'
&\FOHWHVW3OXV'1$5HDJHQW.LWZDVXVHG IRU VDPSOH VWDLQLQJ DFFRUGLQJ WR PDQXIDFWXUHU¶V
LQVWUXFWLRQV 6DPSOHV ZHUH UXQ RQ D %' -FRORU )$&6&DOLEXU DQG UHVXOWV DQDO\]HG XVLQJ
)ORZ-R 
 
;HQRJUDIWPRXVHPRGHO 
$QLPDOZRUNZDVDSSURYHGE\WKH&58.-0,(WKLFDO5HYLHZ&RPPLWWHHDQGZDVSHUIRUPHG
ZLWKLQWKHOLPLWVRIDOLFHQVHJUDQWHGE\WKH+RPH2IILFHDFFRUGLQJWRWKH$QLPDOV6FLHQWLILF
3URFHGXUHV$FW 
)RULQGXFLEOHNQRFNGRZQ[HQRJUDIWV[&$/-VKFHOOVZHUHLQMHFWHGVFLQWRWKH
ULJKW SRVWHULRU IODQNV RI ± ZHHN-ROG LPPXQRGHILFLHQW 12'-VFLG ,/5JDPPDQXOO
16* IHPDOHPLFHPLFHREWDLQHGIURP&KDUOHV5LYHU8.0LFHZHLJKHGEHWZHHQ±
JDW WKH VWDUWRI H[SHULPHQW:KHQ WXPRUV UHDFKHGDYROXPHRIDSSUR[LPDWHO\PP
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PLFH  SHU JURXS ZHUH UDQGRPO\ DVVLJQHG WR WUHDWPHQW ZLWK FRQWURO RU GR[\F\FOLQH GLHW
VVQLII 
)RU SDUHQWDO FHOO [HQRJUDIWV [ &$/ FHOOV ZHUH LQMHFWHG VF LQWR WKH ULJKW
SRVWHULRUIODQNVRI±ZHHN-ROGLPPXQRGHILFLHQW16*IHPDOHPLFHPLFHREWDLQHGIURP
&KDUOHV5LYHU8.0LFHZHLJKHGEHWZHHQ±JDWWKHVWDUWRIH[SHULPHQW:KHQWXPRUV
UHDFKHGDYROXPHRIDSSUR[LPDWHO\PPPLFHSHUJURXSZHUHDVVLJQHGWRWUHDWPHQW
ZLWKFRQWURORUGR[\F\FOLQHGLHWVVQLII 
7XPRU IRUPDWLRQ ZDVPRQLWRUHG HYHU\ IHZGD\V DQG WXPRU YROXPHEDVHGRQ FDOLSHU
PHDVXUHPHQWV ZDV FDOFXODWHG E\ WKH IRUPXOD WXPRU YROXPH   OHQJWK [ ZLGWK [ ZLGWK
0LFH ZHUH FXOOHG ZKHQ WXPRUV UHDFKHG PD[LPXP SHUPLWWHG YROXPH  PP RU DIWHU 
ZHHNVSRVW-LQMHFWLRQRIFHOOV 
 
6WDWLVWLFDODQDO\VLV 
(UURU EDUV VKRZQ RQ JUDSKV UHSUHVHQW 6(0 7ZR-WDLOHG :HOFK¶V W-WHVW ZDV XVHG WR DVVHVV
VLJQLILFDQFHRIGLIIHUHQFHVEHWZHHQJURXSVIRUDVVD\V$QDO\VLVRIYDULDQFH$129$DQDO\VLV
ZDVFRQGXFWHGWRDVVHVVWKHVLJQLILFDQFHRIGLIIHUHQFHVLQP51$H[SUHVVLRQEHWZHHQJURXSV
EDVHGRQ*,67,&FRS\QXPEHUV 
 
&RS\QXPEHUDQDO\VLV 
'1$ IURP FHOO OLQHV ZDV SUHSDUHG XVLQJ D 4LDJHQ %ORRG 	 7LVVXH NLW DFFRUGLQJ WR
PDQXIDFWXUHU¶V LQVWUXFWLRQV &RS\ QXPEHU DQDO\VLV ZDV FRQGXFWHG E\ SDLUHG-HQG ZKROH
JHQRPH VHTXHQFLQJ  [  ES UHDGV RQ DQ ,OOXPLQD +L6HT   PLOOLRQ SDLUV SHU
VDPSOHVZHUH JHQHUDWHGZKLFKJDYH aWZR-IROG FRYHUDJH RI WKHJHQRPH7KH PRVW FRPPRQ
SORLG\ ZDV GHILQHG DV µQRUPDO¶ IRU WKH SXUSRVHV RI DVVHVVLQJ FRS\ QXPEHU JDLQ DQG ORVV
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$QDO\VLVZDVUXQDFFRUGLQJ WRSUHYLRXVO\SXEOLVKHGSURFHGXUHV1RYLUDOJHQRPHVZHUH
GHWHFWHG LQ DQ\ VDPSOH VR FHOO OLQHV ZHUH GHWHUPLQHG WR EH +39-QHJDWLYH ZLWK 
FRQILGHQFH 
 
  
 15 
RESULTS 
Amplification and expression of LZK/MAP3K13 in HNSCC 
Examination of data from The Cancer Genome Atlas (TCGA) revealed that high level 
amplification of MAP3K13 was present in 20% of HNSCC tumors (Fig. 1A), while an additional 
56% had copy number gain (38). Furthermore, MAP3K13 was within the top 100 most 
frequently amplified genes on chromosome 3 (Fig. 1B). Further analysis of TCGA tumor 
samples indicated that higher MAP3K13 copy number was associated with significantly 
increased mRNA expression (Fig. 1C). In addition, data from the Cancer Cell Line Encyclopedia 
(CCLE) showed that upper aerodigestive tract (UADT) cell lines have the highest levels of 
MAP3K13 mRNA compared with all other available cancer cell lines (Supplementary Fig. S1A) 
(39).  
LZK expression levels were assessed in a panel of HNSCC cell lines with 3q gain based 
on CCLE data. Control cell lines included BEAS2B immortalized bronchial epithelial cells and 
OKF6/TERT2 immortalized oral keratinocytes; both cell lines were diploid with no change at 3q 
(Fig 1D). Copy number analysis confirmed the presence of the 3q amplicon in almost all 
HNSCC cell lines tested (Fig. 1D). MSK921 was the only HNSCC cell line tested that had no 
alteration at 3q (Fig. 1D). BICR22 was notable for the fact that its region of copy number gain 
did not encompass MAP3K13 (Fig. 1D). Therefore, BICR22 and MSK921 were chosen as 
control HNSCC cell lines. qRT-PCR showed that a majority of the cell lines with copy number 
gain of MAP3K13 had increased mRNA expression (Fig. 1E), confirming data observed for 
TCGA human primary tumor samples. Finally, western blot analysis indicated increased LZK 
protein levels in cells with 3q gain compared with BEAS2B cells (Supplementary Fig. S1B).  
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LZK knockdown by siRNA reduces viability of HNSCC cells with copy number gain 
To determine whether LZK is important for maintaining tumorigenic phenotypes, siRNA-
mediated knockdown was conducted. Three individual siRNAs effectively depleted LZK 
protein levels in CAL33 and BICR56 HNSCC cells, and in OKF6/TERT2 and BEAS2B 
control lines (Fig. 2A). All three LZK siRNAs caused a highly significant reduction in viability 
in CAL33 and BICR56 cells, but had no effect on BEAS2B or OKF6/TERT2 cells (Fig. 2B). 
In addition, crystal violet staining, which was used to assess relative cell growth and survival, 
showed that knockdown of LZK decreased the cell density of CAL33 and BICR56 cells (Fig. 
2C±D). No effect was observed in OKF6/TERT2 controls, although a minor reduction in cell 
density was seen for BEAS2B cells with siLZKB and siLZKC (Fig. 2C±D). 
 
LZK knockdown by doxycycline-inducible shRNA reduces viability, colony formation, 
and growth in vivo of HNSCC cells with 3q gain 
To validate these data, HNSCC cells with doxycycline-inducible expression of shRNA 
targeting MAP3K13 were generated (Fig. 3A±B). Induced knockdown of LZK led to a 40±50% 
reduction in viability of CAL33 and BICR56 cells, but had no significant effect on viability of 
MSK921 or BICR22 control cell lines that lack MAP3K13 copy number gain (Fig. 3C). 
Consistent with these results, there was a ~50% decrease in crystal violet staining in CAL33 
and BICR56 cells after doxycycline-induced LZK knockdown, but no effect on MSK921 or 
BICR22 cells (Supplementary Fig. S2A±B). To confirm these data in a 3D setting that more 
closely mimics the tumor microenvironment, cells were grown in matrigel; colony sizes of 
CAL33 and BICR56 cells were reduced after LZK knockdown, whereas no significant effect 
was seen for control cell lines (Fig. 3D±E). Clonogenicity was then assessed; a near complete 
ablation of colony forming ability was observed for CAL33 and BICR56 cells after depletion 
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of LZK (Fig. 3F, Supplementary Fig. S2C). MSK921 cells showed a smaller reduction in 
colony formation after doxycycline treatment; this effect occurred at least in part due to the 
toxicity of doxycycline, which also affected the parental cell line (Fig. 3F, Supplementary Fig. 
S2C). Doxycycline has been reported to have toxic effects on some cell lines (40,41), and this 
toxicity is likely more pronounced when cells are seeded at a low density (42), which could 
explain why these effects were not seen in short-term assays. LZK depletion did not suppress 
growth of BICR22 cells (Fig. 3F, Supplementary Fig. S2C).  
Critically, re-expression of the sh1-resistant LZK construct into CAL33-sh1 and 
BICR56-sh1 cells fully or partially, respectively, rescued the effect of LZK knockdown on cell 
density, confirming that these effects were specific to LZK depletion (Fig. 4A). LZK 
knockdown was then conducted in additional control and HNSCC cell lines (Fig. 4B). shRNA-
mediated depletion of LZK resulted in a significant reduction in colony formation in two 
additional HNSCC lines with 3q gain (BICR6 and DETROIT562), but not in BEAS2B or 
OKF6/TERT2 immortalized control cell lines (Fig. 4C±D). To determine the importance of 
LZK in vivo, we established a murine xenograft model using the CAL33-sh1 cell line. There 
was a significant reduction in tumor growth of 39% ± 16% upon doxycycline treatment (Fig. 
4E; note doxycycline diet had no significant effect on parental CAL33 xenografts 
(Supplementary Fig. S3A)). These results highlight the importance of LZK as a regulator of 
viability in HNSCC. 
 
LZK knockdown by doxycycline-inducible shRNA reduces proliferation and cell cycle 
progression of HNSCC cells with copy number gain  
Phenotypic assays were then carried out to investigate potential mechanisms of reduced 
viability. BrdU assays showed that depletion of LZK significantly reduced proliferation of 
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CAL33 and BICR56 cells, while no effects were observed in control cells (Fig. 5A). The 
decrease seen was to a similar extent as that observed in viability and density assays, 
suggesting that this proliferative decrease may be the main mechanism underpinning these 
effects. To confirm these results, propidium iodide staining was used to assess the effect of 
LZK knockdown on progression through the cell cycle. An increase in the percentage of cells 
in G1 phase was observed for CAL33 and BICR56 inducible knockdown cells depleted of 
LZK, but not for MSK921 control cells (Fig. 5B, Supplementary Table S1). This correlated 
with an increase in G1/S ratio, a measure of cell cycle arrest, of approximately three-fold for 
CAL33 and two-fold for BICR56 (Fig. 5C). These data verify that LZK regulates HNSCC 
viability through regulation of the cell cycle. Additionally, PARP cleavage, a marker of 
apoptosis, was not observed after LZK knockdown (Supplementary Fig. S3B), suggesting that 
LZK does not regulate cell death in HNSCC.  
 
LZK knockdown leads to a reduction in levels of stabilized mutant p53  
To identify pathways involved in the pro-proliferative effect of LZK, we monitored the 
activation status of pathways described to be activated by LZK: JNK (12,13), p38 (13), and 
1)ț% (14) (Supplementary Fig. S4A). In overexpression assays we observed activation of 
JNK EXW QRW S RU 1)ț% (Supplementary Fig. S4B±F). However, in BICR56 and CAL33 
cells, there was no decrease in phospho-JNK after transient or inducible knockdown 
(Supplementary Fig. S4G±H; note that minor reductions were observed for MSK921 cells, but 
this was also seen in parental MSK921 cells, suggesting that doxycycline may be responsible 
for the reduction in pJNK in this cell line). This suggested that these pathways were not 
responsible for the reduced proliferation observed after LZK depletion.  
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To elucidate other pathways regulated by LZK, a phospho-kinase array was conducted 
using CAL33 inducible knockdown cells. The most obvious differences seen were for three 
p53 phosphorylation sites (S15, S46 and S392) (Fig. 6A). The phospho-p53 results were 
validated by western blot for the S392 phospho-site; however, it was found that total p53 levels 
were reduced after LZK knockdown (Fig. 6B), accounting for the observed decrease in 
phospho-p53 at the three phospho-sites. Effects on p53 were then investigated in BICR56 
cells; p53 levels were also markedly reduced in this cell line after depletion of LZK (Fig. 6C). 
No reductions in total p53 were observed in MSK921 cells (Fig. 6C; note doxycycline 
treatment alone did not alter p53 levels in parental cells (Supplementary Fig. S5A)).  
Notably, CAL33 has a known GOF mutation in p53 (R175H), so a decrease in total p53 
would be expected to lead to reduced proliferation. In contrast, the MSK921 control cell line 
harbors wild-type p53. BICR56 has a mutation in p53 that leads to the exclusion of seven 
amino acids (Y126±K132) at the beginning of exon 5. To date, this mutant has not been 
characterized. Transient knockdown using siRNA was conducted to investigate the function of 
p53 in these cell lines (Supplementary Fig. S5B±C). Knockdown of p53 in CAL33 cells led to 
a 40±60% reduction in viability (Fig. 6D; Supplementary Fig. S5C), indicating that LZK 
primarily promotes viability by maintaining expression of GOF mutant p53 in these cells. In 
BICR56 cells, knockdown of p53 led to a smaller but significant decrease in viability of 30± 
40% (Fig. 6D; Supplementary Fig. S5C), suggesting that these cells also require expression of 
stabilized mutant p53.  
To determine if E3 ubiquitin ligases MDM2 or MDM4 were contributing to loss of 
expression of GOF mutant p53, expression of these two proteins was monitored in cells 
depleted of LZK. Endogenous MDM4 was not detected in any of the HNSCC cell lines and 
endogenous MDM2 was only detected in the CAL33 cells (Supplementary Fig. S6A). There 
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was no increase in MDM2 protein levels in CAL33 cells depleted of LZK (Supplementary Fig. 
S6B). Overall, these data indicate that regulation of these E3 ubiquitin ligases is not an 
underlying mechanism contributing to loss of p53 expression in HNSCC cells depleted of 
LZK.  
To further understand the mechanism by which the LZK-GOF p53 pathway is 
promoting increased proliferation we assessed activation and expression of targets downstream 
of GOF mutant p53 (22,27). Depletion of LZK resulted in increased levels of p21 and 
phospho-AMPKĮ in CAL33 and BICR56 cells (Fig. 6E), consistent with previous reports that 
GOF mutant p53 suppresses these downstream targets. These results highlight a novel 
signaling pathway where LZK is required to maintain expression of GOF mutant p53, which 
regulates activation of AMPK and expression of p21. Finally, re-expression of 
shRNA-resistant LZK in CAL33 and BICR56 cells restored levels of mutant p53, 
demonstrating that this effect was specifically due to depletion of LZK (Fig. 6F).  
 
DISCUSSION 
HNSCC accounts for approximately 600,000 cases and 350,000 deaths per year worldwide 
(43,44). A majority of patients present with stage III or IV disease, and, after treatment, 50% 
will have disease progression within 2 years (45,46). 5-year survival rates for patients who 
present with advanced disease are under 50% (47). At present, the current treatment regimens 
for later stages involve chemotherapy and/or radiotherapy, which carry significant toxicities 
(46,48). Chemotherapy or radiotherapy can be enhanced by combination with cetuximab, 
which targets EGFR, in advanced stages of the disease (49,50). EGFR is overexpressed in 
~90% of HNSCC patients; however, only a small subset (13%) of patients respond to 
cetuximab monotherapy (51). Additionally, the inclusion of cetuximab to a regimen of 
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chemoradiotherapy was not found to have any additional benefit, regardless of EGFR 
expression levels (52). Cetuximab is the only FDA approved targeted therapy for the treatment 
of HNSCC patients, and a recent review of current clinical trials for HNSCC indicated that a 
majority of trials are centered around EGFR inhibitors, including gefitinib and erlotinib, in 
combination with chemotherapy and/or radiotherapy (44). This highlights the intense need for 
the development of new therapies for the treatment of this disease. 
The development of novel therapies has been hampered by the relative rarity of 
targetable mutations in HNSCC. The exception is PIK3CA, which is mutated in ~20% of 
HNSCC samples (1,10), representing a cohort of patients that may benefit from treatment with 
PI3K/AKT inhibitors. In addition, recent studies have indicated that inhibitors targeting the 
mTOR and ERK pathways hold promise for treatment of HNSCC patients, including patients 
positive for PIK3CA mutations (53-55).  
Rather than targetable mutations, the most common genetic alterations in HNSCC are 
somatic copy number alterations, the most frequent of which is copy number gain at 3q (1). 
Multiple genes on the 3q amplicon can promote tumorigenic phenotypes, including PIK3CA 
(2,3), TP63 (4-6), and SOX2 (7-9), and detailed studies must be undertaken to define the 
contribution of the various genes on this amplicon to tumor initiation and maintenance. 
MAP3K13 (LZK) is another resident gene of the 3q amplicon. Here, we have shown that 
knockdown of LZK reduced proliferation specifically in HNSCC cells with 3q gain, an effect 
which was rescued by re-expression of shRNA-resistant LZK. Our data identify LZK as novel 
genetic dependency in HNSCC tumors harboring the 3q amplicon, and suggest LZK as a 
potential therapeutic target in HNSCC. Future studies will explore the potential of LZK 
inhibitors for the treatment of head and neck cancers harboring the 3q amplicon, both alone 
and in combination with other inhibitors, for example targeting PI3K, AKT, and mTOR.  
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Knockdown of LZK led to a reduction in protein levels of GOF mutant p53 in cells 
with 3q gain; this was also rescued by re-expression of shRNA-resistant LZK. GOF mutant 
p53 has been well documented to promote proliferation (24-26). In contrast to the wild-type 
protein, GOF mutant p53 is found at constitutively high levels in cancer cells (18). However, 
the mutant proteins are not inherently more stable than the wild-type, as demonstrated by 
expression in normal tissue compared with tumor tissue in transgenic mice (34); this implies 
that GOF mutants are stabilized by tumor cell-specific factors. Our study highlights amplified 
LZK as one potential contributor to the maintenance of mutant p53 stability in HNSCC cells. 
When LZK was depleted, we also observed increases in levels of phospho-AMPK and p21, 
both of which are negatively regulated by GOF p53 (22,27). Based on these observations, we 
propose a model whereby amplified LZK promotes stability of GOF mutant p53, which in turn 
promotes proliferation of HNSCC cells via regulation of its downstream targets, including p21 
and AMPK (Fig. 6G). The mechanism by which LZK stabilizes mutant p53 will be the focus 
of future studies. 
In summary, our data indicate that LZK promotes proliferation in HNSCC with 3q 
copy number gain, via maintaining expression of stabilized mutant p53. Enzymes that regulate 
stability of GOF mutant p53 are attractive targets given the incidence of stabilized mutant p53 
across all cancers. It was recently reported that over 11 million cancer patients live with 
stabilized mutant p53 (23); thus, LZK may represent a druggable genetic dependency for a 
subset of these patients where LZK is amplified.  
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Figure 1. Amplification and expression of MAP3K13 (LZK) in HNSCC. (A) Amplification 
of MAP3K13 in 20% of HNSCC tumor samples from TCGA dataset. Graphic from cBio 
Portal. (B) Graph representing percentage of HNSCC patients with amplification of each gene 
on chromosome 3, according to TCGA. MAP3K13 is marked with a red cross. (C) Increased 
copy number of MAP3K13 leads to an increase in mRNA expression levels. RNAseq 
expression data and GISTIC copy number scores were extracted from the cBio portal. Box 
plots compare expression of MAP3K13 across different GISTIC copy number scores 
where -1=loss of heterozygosity, 0=diploid, 1=gain and 2=amplification. ANOVA p-value 
2.3e-11. (D) Copy number gain of MAP3K13 in HNSCC cell lines. Copy number analysis was 
conducted by whole genome sequencing to determine which cell lines harbored the 3q 
amplicon. Data for chromosome 3 are shown. Most HNSCC cell lines have amplification of 3q 
(as compared with the overall average ploidy of each cell line, shown by black y-indicator 
line), whereas control cell lines do not (BEAS2B immortalized bronchial epithelial cells, 
OKF6/TERT2 immortalized oral keratinocytes, and MSK921 HNSCC cells). Mutational status 
of p53 is indicated underneath each cell line. (E) qRT-PCR shows increased MAP3K13 mRNA 
expression in HNSCC lines with 3q copy number gain relative to controls. Results were 
normalized to ACTB ȕ-actin) control gene and then to OKF6/TERT2 control cell line. Black = 
immortalized control cells, blue = HNSCC cells without MAP3K13 gain, green = HNSCC cells 
with MAP3K13 gain. 
 
Figure 2. LZK knockdown by siRNA reduces relative cell density and viability of 
HNSCC cells with copy number gain. (A) LZK is knocked down in HNSCC and 
immortalized control cell lines by three separate siRNAs. Cells were reverse transfected for 
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24 h (CAL33 and BICR56) or 48 h (BEAS2B) with 10 nM LZK or non-targeting control 
siRNA. Forward transfection for 72 h was used for OKF6/TERT2 cells. (B) Knockdown of 
LZK reduces viability of CAL33 and BICR56 HNSCC cells, but has no effect on BEAS2B 
OKF6/TERT2 cells. Cells were transfected in triplicate and analyzed by MTT assay 72 h later. 
Graph shows average of at least three independent experiments and error bars indicate ±SEM. 
**t-test p-value of <0.005 compared with relevant negative control result. Two-WDLOHG:HOFK¶V
t-test used. (C) Knockdown of LZK reduces relative cell density of CAL33 and BICR56 cells 
as compared with BEAS2B and OKF6/TERT2 controls. Cells were incubated for 72 h after 
transfection, fixed with methanol and stained with crystal violet solution. (D) Crystal violet 
was solubilized in 10% acetic acid and read at 595 nm to quantify results. Results averaged 
from at least three independent experiments and expressed relative to siNeg. Error bars 
represent ±SEM. **t-test p-value of <0.005 compared with relevant negative control result. *t-
test p-value of <0.05 compared with relevant negative control result. Two-WDLOHG:HOFK¶VW-test 
used.  
 
Figure 3. LZK knockdown by doxycycline-inducible shRNA reduces relative cell density, 
viability and colony forming potential of HNSCC cells with copy number gain. 
(A) Induction of shRNA by doxycycline reduces MAP3K13 mRNA in BICR56, CAL33, 
BICR22 and MSK921 inducible knockdown cells. Knockdown was assessed by RT-PCR after 
48 h induction. (B) qRT-PCR shows knockdown of MAP3K13 in inducible knockdown lines 
after 48 h doxycycline-induction, as compared with control genes (B2M or ACTB). (C) 
Knockdown of LZK reduces viability of CAL33 and BICR56 HNSCC cell lines, but has no 
effect on MSK921 or BICR22 cells. Cells were induced in triplicate and analyzed by MTT 
assay 72 h later. Graph shows average of at least three independent experiments and error bars 
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indicate ±SEM. **t-test p-value of <0.005 compared with relevant untreated control result. *t-
test p-value of <0.05 compared with relevant untreated control. NS = not significant. Two-
WDLOHG:HOFK¶VW-test used. (D) Knockdown of LZK reduces cell growth of CAL33 and BICR56 
cells in matrigel as compared with MSK921 and BICR22 control cell lines. Cells were 
incubated for 72 h after doxycycline treatment, and visualized using an inverted light 
PLFURVFRSH6FDOHEDUUHSUHVHQWVȝP(E) 7KHµ&RORU7KUHVKROG¶WRROLQ,PDJH-ZDVXVHG
to assess average colony size of cells visualized in (D). Three images per condition were used 
for measurement, and average colony size for each calculated. Values expressed relative to 
untreated control. Error bars represent ±SEM. **t-test p-value of <0.005 compared with 
relevant negative control result. Two-WDLOHG :HOFK¶V W-test used. (F) Knockdown of LZK 
reduces colony forming ability of CAL33 and BICR56 cells as compared with BICR22 and 
MSK921 controls. Cells were seeded at 1000/well in 6-well plates in triplicate and treated with 
doxycycline for 14 days before fixing with methanol and staining with crystal violet. 
 
Figure 4. Confirmation of pro-proliferative effect of amplified LZK in vitro and in vivo. 
(A) Reduction in relative cell density after LZK knockdown is rescued by expression of 
shRNA-resistant LZK. Full rescue achieved for CAL33 and partial rescue for BICR56. Cells 
with inducible sh1 construct were transiently transfected 24 h after seeding with FLAG-tagged 
shRNA-resistant LZK (shRes) or empty vector (EV) control. Eight hours after transfection, 
PHGLXPZDVFKDQJHGDQGȝJPOGoxycycline added where required. Cells were stained with 
FU\VWDOYLROHWKDIWHUWUDQVIHFWLRQ:HOFK¶VWZR-tailed t-test p-value of <0.05. (B) qRT-PCR 
shows knockdown of MAP3K13 in sh3 inducible knockdown lines after 48 h doxycycline-
induction, as compared with ACTB reference gene. (C) Doxycycline-induced knockdown of 
LZK reduces colony formation of additional HNSCC cell lines with 3q gain (BICR6 and 
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DETROIT562), but not immortalized control cell lines. Cells were seeded in triplicate and 
treated with doxycycline for 2 weeks prior to crystal violet staining. (D) Quantification of 
results visualized in (C). **t-test p-value of <0.005 compared with corresponding doxycycline-
treated parental cells. Two-WDLOHG:HOFK¶VW-test used. (E)'R[\F\FOLQH-LQGXFHGNQRFNGRZQRI
/=. UHGXFHV WXPRU JURZWK RI &$/ FHOOV E\     [  &$/ FHOOV ZLWK
LQGXFLEOHNQRFNGRZQRI/=.ZHUHHQJUDIWHG LQ16*PLFH After tumor establishment, mice 
were randomized and treated with doxycycline or control diet. 7XPRUYROXPHEDVHGRQFDOLSHU
PHDVXUHPHQWV ZDV FDOFXODWHG E\ WKH IRUPXOD WXPRU YROXPH   OHQJWK [ ZLGWK [ ZLGWK
Mean tumor volumes ±SEM are shown (n=10 mice/group), **p<0.005. 
 
Figure 5. LZK knockdown by doxycycline-inducible shRNA reduces proliferation and 
cell cycle progression of HNSCC cells with copy number gain. (A) Knockdown of LZK 
reduces proliferation of CAL33 and BICR56 cells as compared with BICR22 and MSK921. 
Cells were incubated for 48 h after doxycycline treatment, then BrdU label added for a further 
24 h before analysis. Graph shows average of at least three independent experiments and error 
bars indicate ±SEM. For MSK921 control cells, minor but significant effect of doxycycline is 
seen for inducible knockdown cells, but this is not significant when compared with 
doxycycline-treated parental cells. **t-test p-value of <0.005 compared with relevant untreated 
control result. *t-test p-value of <0.05 compared to relevant untreated control. NS = not 
significant. Two-WDLOHG:HOFK¶VW-test used. (B) LZK knockdown leads to an increase in cells in 
G1 phase in CAL33 and BICR56 cells, but not in MSK921 controls. Histograms show cell 
count vs FL2-A (propidium iodide) for inducible knockdown cells. Cells were induced with 
1 ȝJPOGR[\F\FOLQHKDIWHUVHHGLQJDQGLQFXEated for 48 h before collection. Once stained, 
cells were analyzed on a 3-color FACSCalibur. (C) G1/S ratio is increased for CAL33 and 
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BICR56 cells after doxycycline-induced LZK knockdown. Graph shows an average of at least 
three independent experiments and error bars indicate ±SEM. **t-test p-value of <0.005 
compared with relevant untreated control result. *t-test p-value of <0.05 compared with 
relevant untreated control. Two-WDLOHG:HOFK¶VW-test used. 
 
Figure 6. LZK knockdown leads to a reduction in levels of stabilized mutant p53. (A) 
Phosphoarray conducted after inducible knockdown of LZK in CAL33 cells indicates 
reduction in phospho-p53 (p-p53) at three different phosphorylation sites. Cells were treated 
ZLWK  ȝJPO GR[\F\FOLQH IRU  K EHIRUH O\VLV (B) Validation of phosphoarray results in 
CAL33 cells. p-p53 reduction found to be due to a decrease in total p53 levels. Cells were 
WUHDWHGZLWKȝJPOGR[\F\FOLQHIRUKEHIRUHO\VLV(C) Extension of experiment to further 
inducible knockdown cell lines. BICR56 cells also show a clear decrease in p53 after LZK 
knockdown, while there is no effect in MSK921 cells. (D) MTT assay to assess viability of 
cells after combination of doxycycline-induced LZK knockdown and transient p53 
knockdown. p53 knockdown reduces viability of BICR56 and CAL33 cells, indicating that 
stabilized mutant p53 is required to maintain viability. Cells were reverse transfected in 
triplicate with 100 nM siRNA to p53 (si-p53#1 used in this experiment) or non-targeting 
control, and induFHGZLWKȝJPOGR[\F\FOLQHZKHUHDSSURSULDWHDWWKHVDPHWLPH077ZDV
read after 72 h. Graph shows average of at least three independent experiments and error bars 
LQGLFDWH 6(0 :HOFK¶V WZR-tailed t-test p-value of <0.005. (E) Reduction in stabilized 
PXWDQWSDIWHU/=.NQRFNGRZQLVDVVRFLDWHGZLWKLQFUHDVHGOHYHOVRIS$03.ĮDQGSLQ
cells with 3q gain, but not MSK921 control cells. (F) Western blots after rescue with shRNA-
resistant LZK show partial rescue of p53 levels, confirming that this effect is specific to 
depletion of LZK. Cells with inducible sh1 construct were transiently transfected 24 h after 
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seeding with FLAG-tagged shRNA-resistant LZK (shRes) or empty vector (EV) control. Eight 
KRXUV DIWHU WUDQVIHFWLRQ PHGLXP ZDV FKDQJHG DQG  ȝJPl doxycycline was added where 
indicated. Cells were lysed 48 h after transfection. (G) Model proposing the pathway by which 
amplified LZK promotes proliferation in HNSCC. LZK contributes to GOF mutant p53 
stability, which promotes proliferation via regulation of its downstream targets, including p21 
and AMPK. 
 
 
 
 
 
 
 






